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Chronic lymphocytic leukemia (CLL) is characterized by extremely variable clinical course indicating
substantial differences in the biology of the disease. Molecular characterization provides new insights
useful for treatment decision making. We report on a patient diagnosed with CLL, whose disease was
characterized by episodes of rapid progression and disease stabilization, and in which a SRSF2 gene
mutation was identiﬁed in the absence of other commonly known mutations of CLL. To the best of our
knowledge this is the ﬁrst case of SRSF2 gene mutation ever reported in CLL.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Chronic lymphocytic leukemia (CLL) is the most frequent he-
matologic neoplasm in Western countries. The clinical course of
chronic lymphocytic leukemia ranges from a very indolent dis-
order with a normal lifespan, to a rapidly progressive disease
leading to death. The variable clinical course of CLL is driven, at
least in part, by the disease molecular heterogeneity. This makes it
difﬁcult to select treatment choice and estimate survival [1]. Most
common chromosome abnormalities of CLL are deletions (6q, 11q,
13q, or 17p) and less frequently chromosomal gains (trisomy 12).
Molecular markers with prognostic impact include inactivating
mutations of TP53, NOTCH1, SF3B1 and baculoviral IAP repeat
containing 3 (BIRC3) genes. Molecular genotyping of CLL enhances
our understanding of the clinical heterogeneity of the disease and
provides new insights useful for treatment decision making [2,3].
Splicing machinery dysfunctions have been associated to CLL,
in particular SF3B1 gene mutations (splicing factor 3B subunit 1)
which are present in about 15% of patients [4]. To our knowledge,
no SRSF2 gene mutation has ever been detected in CLL. In order to
broaden our knowledge on the frequency of SRSF2 splicingaccess article under the CC BY-NC
Via del Fosso di Fiorano 64,
uera).mutations in CLL we studied systematically peripheral blood
samples with a DNA high-resolution melting analysis test [5] in a
cohort of 115 patients diagnosed with CLL (Table 1) and found only
1 mutated case.
We report on a patient diagnosed with chronic lymphocytic
leukemia (CLL) whose disease was characterized by marked clin-
ical heterogeneity with episodes of rapid progression and disease
stabilization and in which a SRSF2 gene mutation was identiﬁed in
the absence of other commonly known mutations of CLL.
A female patient aged 55 was observed in December 1995 at
Sant' Eugenio hospital in Rome with lymphocytosis. The patient
past medical records included: malaria 7 years before, bilateral
oophorectomy and hysterectomy due to uterine ﬁbroma, and hy-
pothyroidism under medication with levothyroxine sodium. La-
boratory tests disclosed 19,7109 L leukocytes (15,5109 L lym-
phocytes), hemoglobin 130 g/L, 218109 L platelets and normal
levels of β2-microglobulin and lactate dehydrogenase. The mi-
croscopic analysis of blood smear was consistent with a lympho-
proliferative process with multiple mature-like small lymphocytes
with scant cytoplasm, regular nucleus (dense chromatin without
nucleoli) and presence of Gümprecht cells. Flow cytometry ana-
lysis showed positivity for: CD5, CD23, CD 19 (LLCr score 5) CD38
and ZAP-70, with restriction to lambda light chain. The IGHV-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics.
Parameter Category Study population
(n¼110)
Gender Male (%) 57 (51.8%)
Age (years old), median (range) 64 (39–83)
RAI stage 0 37 (33.6%)
I–II 73 (66.4%)
WBC (109/L), median (range) 19,52 (7,64–270,38)
Lymphocytes (109/L), median
(range)
13,70 (4,20–258,30)
Beta-2-microglobulin Abnormal high le-
vel (%)
28 (25,5%)
Karyotype by ﬂuorescence in situ
hybridization (FISH)
Normal 26 (23.6%)
High risk 38 (34.5%)
Deletion 13p 46 (41.8%)
Lymphadenopathy/splenomegaly
at diagnosis
Presence 37 (33,6%)
Bulky mass Presence 4 (3,6%)
Lymphocytes doubling time o12 months 36 (32,7%)
Necessity of treatment Yes 81 (73.6%)
First time treatmenta FC 53 (48,18%)
RFC 5 (4,54%)
RB 10 (9,09%)
LeukeranþR 3(2,72%)
Leukeran 8(7,27%)
Days to start treatment, median
(range)
977 (7–3935)
Infection grade IVb 19 (17,3%)
Response to treatment Complete remision 50 (61,73%)
Partial remision 24 (29,63%)
Failure/progression 1 (1,23%)
No valuable 6 (7,41%)
Relapse in patients who achieved
complete remission
18 (36%)
Days to relapsec 1258 (386–2725)
a FC – ﬂudarabineþcyclophosfamide. RFC – rituximabþﬂudarabineþ cyclo-
phosfamide. RB – rituximabþbendamustine. R – rituximab.
b Median value of the days passed since complete remission after ﬁrst line
therapy until relapse occurred.
c All patients presenting infection grade IV received treatment (p¼0.01).
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del13q. Sequencing analysis of the following genes resulted ne-
gative for molecular alterations: NOTCH1 (Notch homolog 1,
translocation-associated [Drosophila]) exon 34, NRAS (neuro-
blastoma RAS viral [v-ras] oncogene homolog) exons 1 and 2, KRAS
(Kirsten rat sarcoma viral oncogene homolog) exons 1 and 2 and
TP53 (tumor protein 53) exons 3, 4, 5, 6, 7 and 8 (exons 9–11 were
excluded due to low mutation frequency). High resolution melting
analysis screening for common mutations of IDH1/2 (isocitrate
dehydrogenase 1 and 2 [NADPþ]) and SF3B1 (exons 12–15) genes
resulted as well negative. Clinically, the patient presented only one
small cervical lymphadenopathy and no systemic symptoms. CLL
was diagnosed as Rai stage I (Rai modiﬁed) and Binet stage A ac-
cording to the International Working group CLL criteria.
The patient did not receive treatment until February 1997 (14
months later) when she rapidly progressed presenting spleno-
megaly and an increased number of lymphadenopathies (Rai II and
Binet B), requiring treatment. A course of intravenous ﬂudarabine
25 mg/Kg/day for 5 days every 28 days for a total of 5 cycles was
prescribed. In June 1997, treatment outcome assessment showed
only partial response (50% reduction of lymphadenopathy).
In December 1998, disease progression was observed with
splenomegaly, increased number of lymphadenopathies and rapid
increase of blood lymphocytes (lymphocyte doubling time o12
months). A course of oral chlorambucil 10 mg/day with prednisone
25 mg/day for 10 days every month was given for a total of 9 cy-
cles. Maintenance therapy was started with subcutaneousinterferon α-2b using alternating doses of 1.5 MU and 3 MU
3 times / week and the patient remained in partial remission for
the following 7 years.
A third disease progression occurred in March 2006 and a
course of ﬂudarabine 25 mg/Kg/day was given for a total of 6 cy-
cles, followed by intravenous rituximab 375 mg/Kg every 28 days
for a total of 4 cycles. Complete remission was achieved at the end
of treatment. An additional cycle of rituximab was administered in
June 2010, At present, the patient remains in complete remission
with residual neutropenia and thrombocytopenia requiring treat-
ment with low dose of prednisone.
SRSF2 mutation was conﬁrmed by Sanger sequencing of dif-
ferent blood DNA samples from the patient during her last two
follow up visits to the hospital in April and June 2014 (Fig. 1).
Unfortunately, DNA from disease onset was not available, making
it difﬁcult to correlate the clinical behavior of the disease with the
presence of SRSF2 mutation. The anomaly could have been ac-
quired as a late event following different treatment lines or, al-
ternatively, it might have been present at diagnosis in the bulk
leukemic population or at sub-clonal level. At diagnosis the patient
presented 13q- as a sole genetic abnormality (which has been
associated to good prognosis) and overexpression of ZAP-70 which
is known to be associated to poor prognosis.
In recent years, there has been growing interest regarding the
role of spliceosome machinery in neoplastic diseases following
evidence of the involvement of splicing factor mutations in diverse
cancers [6]. SRSF2 (Serine-Arginine Splicing Factor 2) is a member
of the serine/arginine (S/A) rich family pre-mRNA splicing factors.
SRSF2mutations are primarily detected in hematologic diseases, at
a reported frequency of 5.5% in refractory anemia with ringed
sideroblasts and refractory cytopenia with multilineage dysplasia
with ringed sideroblasts, 11.6% in myelodysplastic syndrome
(MDS) without ringed sideroblasts, 6.5% in acute myeloblastic
leukemia secondary to MDS, 0.7% in de novo acute myeloid leu-
kemia, 1.9% in myeloproliferative neoplasms, 18.8% in secondary
acute myeloid leukemia evolving from myeloproliferative neo-
plasm and 28.4% in chronic myelomonocytic leukemia (CMML)
[6,7]. In MDS and CMML, SRSF2 point mutations mostly occur in
exon 1 of the SRSF2 gene, at amino acid position P95 (95% and 93%
of cases respectively). In the remaining minority of cases inser-
tions/deletions and frameshifts can be found around amino acid
P95 and also point mutations in other positions such as P96, P84,
P85 and P86 [7,8] have been reported. In MDS and CMML, SRSF2
mutated cases show higher transformation rate, shorter time to
progression to acute myeloid leukemia and shorter overall survival
compared to unmutated cases [7,9,10]. SRSF2 mutations are
thought to interfere with cellular homeostasis via defective spli-
cing of certain genes such as RUNX1 (runt-related transcription
factor 1 gene) with a loss-of-function effect seen in MDS and
CMML [8]. Recent publications have liked SRSF2 mutations with
older male patients with MDS whose clinical course remains
stable with no co-occurrence of other mutations [11].
The frequency of other splicing mutations in CLL besides SF3B1
such as SRSF2 has been studied recently and it is known that
mutations in this gene are uncommon [12–14]. In our study, we
found one case of SRSF2mutation in a patient with CLL with a very
variable clinical course and many relapses. Little can be assumed
in this case due to the lack of similar reports in literature, however
it is possible that the mutation could have contributed to the
worsening of her disease.
Another assumption that arises from this case is that the pre-
sence of myelodysplasia secondary to treatment could explain the
presence of SRSF2 mutation in this patient. This brings us to think
on many relapsed CLL cases with residual cytopenias where no
other molecular abnormalities or disease markers can explain poor
clinical outcomes.
Fig. 1. High resolution melting and sequencing analyses reports. Panel A: gene scanning difference plot showing patient's (LLC-125) sample with a positive melting pattern.
Wilde type (WT) samples are located at the baseline. Panel B: melting peak analysis showing patient's sample with a different (early) melting temperature compared to WT
samples. -d/dT: negative derivative of the change in ﬂuorescence divided by the change in temperature in relation to the temperature. Panel C: sequencing analysis showing
patient's sample with SRSF2 P95L mutation compared to a WT control.
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signiﬁcance of molecular abnormalities in CLL with myelodys-
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